Clinical trials: Advanced Solid Tumors (Phase 1)
Solid Tumors
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in…
- Trial name
- NCT00413686
- Testing
- AZD7762, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Advanced/Metastatic Solid Tumors
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
- Trial name
- NCT03833427
- Testing
- Selumetinib, Pembrolizumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Solid Tumor of Epithelial Origin, Gastric Cancer
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in…
- Trial name
- NCT01466569
- Testing
- AbGn-7
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 13 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Various Advanced Cancer
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors.
- Trial name
- CheckMate358 (NCT02488759)
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- 40 sites in United States, Belgium and 9 more
- Volunteers
- 578 people
- Sponsor
- Bristol-Myers Squibb
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
- Trial name
- NCT03425279
- Testing
- CAB-AXL-ADC, PD-1 inhibitor
- Where
- 40 sites in United States, Hong Kong and 1 more
- Volunteers
- 245 people
- Sponsor
- BioAtla, Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Neoplasms
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
The primary objectives of the study are: To determine the safety and the maximum tolerated dose (MTD) of IPI-926 To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) To recommend a dose…
- Trial name
- NCT00761696
- Testing
- IPI-926
- Where
- 5 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
CLDN6-positive Solid Tumor, Ovarian Cancer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Before a treatment can be approved for use, clinical studies need to be done. This study is for people with certain types of cancer that have become worse and are difficult to treat.
- Conditions
- CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT06681870
- Testing
- ASP1893
- Sponsor
- Astellas Pharma Global Development, Inc.
Major Advanced Solid Tumors Other Than Colorectal
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.
- Trial name
- NCT01405391
- Testing
- PM01183
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- PharmaMar
Ovarian Cancer, Endometrial Cancer
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT06276491
- Testing
- XmAb541
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 282 people
- Sponsor
- Xencor, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Metastatic Cancer, Solid Tumor
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
- Conditions
- Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
- Trial name
- NCT03013218
- Testing
- Evorpacept (ALX148), Pembrolizumab, Trastuzumab
- Where
- 10 sites in United States, South Korea
- Volunteers
- 174 people
- Sponsor
- ALX Oncology Inc.
Solid Tumors
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.
- Trial name
- NCT01071018
- Testing
- MK2206 every other day, MK2206 once weekly
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor
Study of rSIFN-co for Patients With Advanced Solid Tumors
In this EffTox dose escalation study, up to 3 dose levels will be tested. The optimal dose (OD) of rSIFN-co will be determined using the EffTox design.
- Trial name
- NCT02464007
- Testing
- rSIFN-co
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Advanced Solid Tumor
A Study of HC006 in Subjects With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies.
- Trial name
- NCT06304571
- Testing
- HC006
- Where
- China
- Volunteers
- 76 people
- Sponsor
- HC Biopharma Inc.
Tumors, Hypoxia
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors.
- Trial name
- NCT00495144
- Testing
- TH-302
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Threshold Pharmaceuticals
Solid Tumor
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced…
- Trial name
- NCT05749432
- Testing
- Hemay181
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Advanced Cancer
Study of Oral Palifosfamide Tris in Solid Tumors
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
- Trial name
- NCT00607711
- Testing
- oral palifosfamide tris
- Sponsor
- Alaunos Therapeutics
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.